Suramin has been shown to have antiproliferative activity, either by blocking the binding of
growth factors to their receptors or by inhibiting critical cellular enzymes. In 6 different cell …

The effect of suramin on tumor growth and morphology in two different human osteosarcoma
xenografts (LI OSM and L-II OSM) grown in BALB/cA-nu/nu mice was studied. Suramin (total …

Suramin is a novel anticancer agent that blocks the binding of growth factors, including basic
fibroblast growth factor (bFGF), to their receptors. Prior studies showed human and …

In the June 1992 edition of the Journal of Clinical Oncology, Myers el al.(1) reported on 38
cases of metastatic hormone refractory pros tate cancer treated with suramin, a bis …

ADVANCES IN molecular biology and the concept of autocrine-stimulated tumor growth
have provided many novel targets for cancer therapy. Suramin may be regarded as the …

Heading Abstract Purpose. The optimal schedule of administration of suramin has not been
well defined. The purpose of this study was to determine the maximum tolerated dose and …

Suramin is an experimental antineoplastic agent which is currently being tested in clinical
trials for its utility in treating breast and prostate cancer. Recent in vitro studies from our …

Purpose: Toward developing a model to study the mechanism of action of suramin against
prostate cancer, we identified the effect of suramin on the growth of xenografts of the …

Suramin inhibits tumour growth and neoangiogenesis by blocking several growth factor
receptors. In this study the toxicity and efficacy of intralesional delivery of suramin …

Background Suramin inhibits growth of neural crest‐derived cells and is used to treat
adrenocortical cancer and neuroblastoma in clinical trials. The antiproliferative effect of …